MediWound Ltd.
MDWDStock
$14.61−29.14%52W
Market Cap$182.15M
P/E—
Div yield—
Beta0.14
Price Chart
Favorite Metrics
Price vs S&P 500 (26W)-36.25%
Price vs S&P 500 (4W)1.64%
VGM Score30.70
Market Capitalization$182.15M
Earnings Surprise History
Q1 26-0.23est. -0.67
Analyst Recommendations
Mar 2026
Apr 2026
May 2026
Jun 2026
4.17
4.17
4.17
4.17
Industry Peers — Pharmaceutical Preparations(21)
| Symbol | Value Score | Growth Score | Momentum Score | Price |
|---|---|---|---|---|
MDWDMediWound Ltd. | D | F | D | $14.61 |
| DFTXDefinium Therapeutics, Inc. Common Shares | — | — | A | $44.10 |
| RGCRegencell Bioscience Holdings Limited Ordinary Shares | — | — | F | $4.78 |
| TRLVTrulieve Cannabis Corp. | B | C | A | $8.41 |
| CRONCronos Group Inc. Common Share | C | B | B | $2.75 |
| GLASGlass House Brands Inc. | C | C | B | $10.34 |
| TLRYTilray Brands, Inc. Common Stock | B | B | D | $4.35 |
| USNAUSANA Health Sciences Inc | B | D | C | $22.65 |
| CGCCanopy Growth Corporation Common Shares | B | C | C | $0.93 |
| NAGENiagen Bioscience, Inc. Common Stock | C | B | D | $3.40 |
| SNDLSundial Growers Inc. Common Shares | A | C | C | $1.29 |
About
MediWound Ltd is a biopharmaceutical company developing treatments for severe burns and hard-to-heal wounds. Its lead product, NexoBrid, is FDA-approved for eschar removal in severe burns and offers a non-surgical alternative to conventional debridement. The company is advancing a pipeline including EscharEx for chronic wound debridement and MW005 for non-melanoma skin cancer, with revenue primarily generated in the United States.